WealthShield Partners LLC Buys 3,218 Shares of IQVIA Holdings Inc. (NYSE:IQV)

WealthShield Partners LLC grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 36.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 12,064 shares of the medical research company’s stock after purchasing an additional 3,218 shares during the period. WealthShield Partners LLC’s holdings in IQVIA were worth $2,791,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp grew its holdings in shares of IQVIA by 2.5% in the second quarter. State Street Corp now owns 8,451,571 shares of the medical research company’s stock valued at $1,899,660,000 after acquiring an additional 207,148 shares in the last quarter. Alliancebernstein L.P. grew its holdings in shares of IQVIA by 19.1% in the second quarter. Alliancebernstein L.P. now owns 5,942,761 shares of the medical research company’s stock valued at $1,335,754,000 after acquiring an additional 952,850 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of IQVIA by 2.2% in the first quarter. Geode Capital Management LLC now owns 3,804,161 shares of the medical research company’s stock valued at $754,864,000 after acquiring an additional 81,501 shares in the last quarter. Lazard Asset Management LLC grew its holdings in shares of IQVIA by 2.9% in the third quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company’s stock valued at $568,460,000 after acquiring an additional 80,189 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in shares of IQVIA by 3.4% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,325,198 shares of the medical research company’s stock valued at $457,483,000 after acquiring an additional 77,422 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

Shares of IQV stock traded down $2.94 on Wednesday, reaching $242.57. The company’s stock had a trading volume of 533,417 shares, compared to its average volume of 1,011,935. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The company has a market capitalization of $44.03 billion, a P/E ratio of 33.68, a PEG ratio of 2.41 and a beta of 1.50. The stock’s 50 day simple moving average is $238.60 and its 200-day simple moving average is $218.55.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. The company had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same quarter last year, the business posted $2.54 earnings per share. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The disclosure for this sale can be found here. Insiders have sold 41,285 shares of company stock valued at $10,331,003 over the last ninety days. 1.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on IQV shares. Barclays upped their target price on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Guggenheim lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Evercore ISI increased their price objective on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a report on Thursday, February 15th. Finally, Truist Financial increased their price objective on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $256.80.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.